Del 0 - Current Clinical Urology

Prostate Cancer Screening

Second Edition

Häftad, Engelska, 2014

AvDonna Pauler Ankerst,Catherine M. Tangen,Ian M. Thompson

3 129 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

In this second edition, the world's leading experts on prostate cancer detection update the previous edition with the latest findings. It incorporates a series of thoughtful and cutting-edge works from the world's experts in prostate cancer screening.

Produktinformation

Utgivningsdatum2014-11-22
Mått178 x 254 x 26 mm
Vikt644 g
FormatHäftad
SpråkEngelska
SerieCurrent Clinical Urology
Antal sidor397
Upplaga2
FörlagHumana Press Inc.
ISBN9781627038539

Tillhör följande kategorier

Onkologi inom Medicin
Epidemiologi och medicinsk statistik inom Medicin
Urologi inom Medicin
Medicin: allmänt inom Medicin

Trends in Prostate Cancer Screening.- Overview of US Prostate Cancer Trends in the Era of PSA Screening.- Trends in Prostate Cancer Screening: Overview of the UK.- Trends in Prostate Cancer Screening: Canada.- Trends in Prostate Cancer Screening – Overview of Europe.- Prostate-Specific Antigen.- Evolution of Prostate-Specific Antigen for Screening.- The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening.- The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy.- Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer.- PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness.- Risk Assessment for Prostate Cancer.- Nomograms for Prostate Cancer.- Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction.- Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator.- Integration of Risk Assessment in Prostate Cancer Screening.- Family History of Prostate Cancer During Rapidly Increasing Incidence.- Recent Biomarkers for Prostate Cancer.- PSA Isoforms: [?2]proPSA Significant Adjunct to Free PSA.- PCA3.- Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications.- Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case–Control Association Studies.- GSTP1 Hypermethylation for Prostate Cancer Detection.- EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection.- Design and Methodologic Considerations in Biomarker Studies.- Toward a Robust System for Biomarker Triage and Validation – EDRN Experience.- Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification andPrediction.- Pitfalls in Prostate Cancer Biomarker Evaluation Studies.- Building upon Recently Completed and Ongoing Prospective Trials.- Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial.- The Selenium and Vitamin E Cancer Prevention Trial.- PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer.- The European Randomized Study of Screening for Prostate Cancer (ERSPC).

From the reviews of the second edition: "This compilation of 27 chapters written by well known urology experts covers a wide range of topics from trends in PSA screening to PSA isoforms ... .This book is most suitable for statisticians, scientists, or clinicians who wish to draw their own conclusions regarding PSA screening and related topics. ... This book is a superb resource for anyone interested in PSA screening ... . It is also an excellent reference for anyone interested in comparing the various studies and controversies from different healthcare systems ... ." (Jack H. Mydlo, Doody's Review Service, May, 2009)